Krystal Biotech (KRYS) Set to Announce Quarterly Earnings on Monday

Krystal Biotech (NASDAQ:KRYS - Get Free Report) is scheduled to issue its quarterly earnings data before the market opens on Monday, November 4th. Analysts expect the company to announce earnings of $0.84 per share for the quarter. Individual that are interested in registering for the company's earnings conference call can do so using this link.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Monday, August 5th. The company reported $0.53 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.50 by $0.03. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. The firm had revenue of $70.28 million for the quarter, compared to analysts' expectations of $65.27 million. During the same period in the prior year, the business earned ($1.25) EPS. The company's revenue for the quarter was up 70283900.0% compared to the same quarter last year. On average, analysts expect Krystal Biotech to post $3 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Krystal Biotech Price Performance

Shares of Krystal Biotech stock traded down $0.67 during trading on Tuesday, reaching $176.22. 85,217 shares of the company traded hands, compared to its average volume of 329,228. The firm has a market capitalization of $5.03 billion, a PE ratio of 94.23 and a beta of 0.82. The company has a 50 day moving average price of $184.40 and a 200-day moving average price of $179.96. Krystal Biotech has a 1-year low of $93.95 and a 1-year high of $219.34.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $197.76, for a total value of $4,944,000.00. Following the sale, the insider now owns 1,500,882 shares of the company's stock, valued at approximately $296,814,424.32. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 14.10% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on KRYS. Citigroup restated a "neutral" rating and issued a $204.00 target price (up from $195.00) on shares of Krystal Biotech in a research note on Tuesday, August 6th. Chardan Capital upped their target price on Krystal Biotech from $153.00 to $208.00 and gave the stock a "buy" rating in a research report on Monday, August 5th. Cantor Fitzgerald reissued an "overweight" rating on shares of Krystal Biotech in a research report on Thursday, August 29th. William Blair upgraded shares of Krystal Biotech to a "strong-buy" rating in a report on Friday, August 30th. Finally, Stifel Nicolaus raised their price objective on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a "buy" rating in a research note on Wednesday, September 11th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $196.75.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).